Treatment with AVONEX(R) (Interferon Beta-1a) for Two Years Reduces Probability of Reaching More Severe Disability Milestones at Eight Years
PRAGUE, Czech Republic, Oct. 12 /PRNewswire/ -- A post-hoc analysis from a Phase III clinical trial of AVONEX(R) (interferon beta-1a) and post-randomization eight-year follow up shows that six-month sustained progression of disability at two years, using the Expanded Disability Status Scale (EDSS), is a significant predictor of long-term disability, as measured by EDSS milestones of 4.0, 5.0, 6.0 and 7.0 at eight years, in patients with relapsing-remitting multiple sclerosis (RRMS). The analysis suggests that patients taking AVONEX for two years were less likely to experience disability progression over time (eight years) when compared to placebo. These data were announced today at the 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) conference in Prague, Czech Republic.
The analysis involved 160 patients with RRMS who received at least two years of treatment (81 placebo, 79 interferon beta-1a), in the AVONEX Phase III trial and who were re-examined eight years post-randomization. 45 patients met the criteria for two-year disability progression sustained for six months (n=18 AVONEX, 27 placebo). The analysis revealed:
-- Patients initially treated with AVONEX were less likely than patients
initially receiving placebo to progress to EDSS scores of greater than
or equal to 4.0 at eight years
-- Six month sustained EDSS progression during the pivotal two-year trial
was a significant predictor of disability progression eight years later
-- Almost twice as many patients who had sustained progression in EDSS
during the two-year trial progressed to an EDSS of greater than or
equal to 4.0 than patients who did not progress (84% sustained,
versus 44% unsustained)
-- Almost three times as many progressed to an EDSS of greater than or
equal to 6.0 (67% sustained, versus 24% unsustained)
"This new analysis presents further evidence that patients who are treated for two years achieve long-term, clinically significant disability benefits," said Dr. Richard Rudick, vice-chairman of Neurological Institute at the Cleveland Clinic Foundation. "For a person with RRMS, starting and staying with treatment slows disability progression, as measured by EDSS."
EDSS is a common disability outcome measure that is used in multiple sclerosis clinical trials. EDSS greater than or equal to 4.0 signifies relatively severe disability, such as impacting physical coordination or the ability to walk without assistance.
AVONEX is the number one prescribed treatment for relapsing forms of multiple sclerosis (MS) worldwide, and is the only once-a-week MS therapy that is effective after the first attack. AVONEX is also proven to slow the progression of physical disability (as shown by 37% reduction over two years) and reduce the number of relapses. AVONEX has been proven effective in clinical trials for up to three years.
This study was funded by Biogen Idec.
AVONEX is the number one most prescribed treatment for relapsing forms of MS worldwide, with more than 130,000 patients on therapy. It was launched in the U.S. in 1996 and later in Europe for the treatment of relapsing forms of MS to slow the progression of disability and reduce relapses. AVONEX has been proven effective in clinical trials for up to three years. AVONEX is marketed internationally in more than 90 countries. AVONEX was the first treatment approved for patients who have their first clinical MS attack and have a brain MRI scan consistent with MS; this use was approved in Europe in 2002 and in the U.S. in 2003.
The most common side effects associated with AVONEX multiple sclerosis treatment are flu-like symptoms, including myalgia, fever, fatigue, headache, chills, nausea, vomiting, pain and asthenia.
AVONEX should be used with caution in patients with depression or other mood disorders and in patients with seizure disorders. AVONEX should not be used by pregnant women. Patients with cardiac disease should be closely monitored. Patients should also be monitored for signs of hepatic injury. Routine periodic blood chemistry and hematology tests are recommended during treatment with AVONEX. Rare cases of anaphylaxis have been reported. Please see complete prescribing information available at http://www.AVONEX.com.
Copyright©2007 PR Newswire.
All rights reserved